First Interstate Bank Increases Stock Position in Pfizer Inc. $PFE

First Interstate Bank boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 16.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 165,491 shares of the biopharmaceutical company’s stock after acquiring an additional 23,154 shares during the period. First Interstate Bank’s holdings in Pfizer were worth $4,217,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Norges Bank purchased a new position in shares of Pfizer in the 2nd quarter valued at about $2,270,157,000. Vanguard Group Inc. boosted its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Pfizer by 43.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after purchasing an additional 5,662,309 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Pfizer by 75.0% in the third quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after buying an additional 3,722,531 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Pfizer by 84.9% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after buying an additional 3,472,240 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $25.52 on Wednesday. The company has a fifty day simple moving average of $25.38 and a 200-day simple moving average of $24.99. The firm has a market capitalization of $145.07 billion, a price-to-earnings ratio of 14.83 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is 100.00%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: License deal for Matrix‑M adjuvant could accelerate Pfizer’s vaccine programs and support pipeline expansion; this is a concrete R&D/capability win. Novavax enters license agreement with Pfizer for vaccine development
• Positive Sentiment: Recent quarterly results and FY‑2025 guidance (EPS range ~3.00–3.15) show profit generation and set expectations for the year, supporting baseline valuation (beat on EPS, mixed on revenue).
• Neutral Sentiment: JPMorgan conference takeaways highlight industry-wide themes — drug pricing pressure, looming patent cliffs, and dealmaking — that shape mid‑cycle expectations for big pharma including Pfizer. Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
• Neutral Sentiment: Analyst pieces compare Pfizer to peers (e.g., Eli Lilly) on growth outlook and product mix; these comparisons keep PFE under scrutiny but don’t change fundamentals immediately. Which Pharma Stock Stands Taller Right Now: LLY or PFE?
• Neutral Sentiment: Quarterly outlook notes (non‑oncology) — Eliquis strength vs softer COVID sales — imply mixed revenue drivers heading into the next report. What to Expect From Pfizer’s Non-Oncology Business in Q4?
• Neutral Sentiment: Thematic ETF/sector coverage pieces mention PFE exposure among obesity/GLP-1 and vaccine plays, which can attract longer‑term interest but provide limited near‑term price support. Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (PFE)
• Negative Sentiment: CEO Albert Bourla said U.S. drug prices are coming down — investors interpret this as potential margin and top‑line pressure from pricing reform and negotiations. Pfizer CEO Albert Bourla: U.S. drug prices are coming down
• Negative Sentiment: Pfizer is exiting parts of the ViiV HIV joint venture as partners reshuffle stakes, reducing exposure to the JV’s future upside and simplifying the company footprint. Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture
• Negative Sentiment: Longer‑term skepticism persists (coverage pieces noting the stock is down materially from peak due to past trial failures and upcoming patent cliffs), which keeps valuation under pressure and can limit rebounds. Down 55%, Should You Buy the Dip on Pfizer?

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Bank of America dropped their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Citigroup initiated coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $27.88.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.